Home    中文  
 
  • Search
  • lucene Search
  • Citation
  • Fig/Tab
  • Adv Search
Just Accepted  |  Current Issue  |  Archive  |  Featured Articles  |  Most Read  |  Most Download  |  Most Cited

Chinese Journal of Clinicians(Electronic Edition) ›› 2020, Vol. 14 ›› Issue (11): 862-865. doi: 10.3877/cma.j.issn.1674-0785.2020.11.002

Special Issue:

• Expert Forum • Previous Articles     Next Articles

Key issues in stratified treatment of HER2 positive breast cancer at different stages

Xueli Mo1,(), Jie Dong1, Dong Han1   

  1. 1. Department of Breast Diseases, Peking University Shougang Hospital, Beijing 100144, China
  • Received:2020-09-07 Online:2020-11-15 Published:2021-03-23
  • Contact: Xueli Mo

Abstract:

In recent years, the clinical research of anti-HER2 drugs has made many breakthroughs, which has significantly improved the prognosis of HER2 positive breast cancer patients and changed the diagnosis and treatment mode of breast cancer. The 2020 edition of the Chinese Society of Clinical Oncology (CSCO) breast cancer diagnosis and treatment guidelines has made important updates to the pre-operative neoadjuvant treatment, postoperative adjuvant treatment, and recurrence and metastasis management of HER2 positive breast cancer, given treatment recommendations for patients with different stages of breast cancer, and standardized the clinical diagnosis and treatment of this malignancy, aiming to improve the survival rate and the quality of life of patients.

Key words: Breast cancer, Human epidermal growth factor receptor-2, CSCO guideline update

京ICP 备07035254号-20
Copyright © Chinese Journal of Clinicians(Electronic Edition), All Rights Reserved.
Tel: 010-57830845 E-mail: zhlcyszz@cma.org.cn
Powered by Beijing Magtech Co. Ltd